Since patients with NAFLD frequently suffer from coronary heart disease with vulnerable coronary plaques [120], the reported positive effects of PCSK9 inhibitors on plaque stabilization seen in the HUYGENS trial may also be of particular relevance in this ASCVD-risk population [121]. Here, PCSK9 is linked to metabolic dysfunction-associated steatotic liver disease.